New Executive Order Critical to Protecting Patients and Public Health

New Executive Order Critical to Protecting Patients and Public Health

Washington, D.C. (September 20, 2019) – President Trump has signed an executive order focused on spurring the development of new vaccine technologies, prioritizing the production of influenza vaccines and identifying strategies for communicating the importance of influenza vaccination. Ahead of what is expected to be a severe flu season, the Administration has made clear that ensuring patients have access to safe and effective treatments is of great importance.

“There are few national priorities more important than protecting the American people from the next possible pandemic outbreak. The president’s own economic advisers have warned that such an event could cost up to $4 trillion and result in the loss of hundreds of thousands of lives. And as many Americans experience each year, seasonal influenza poses as a serious and even deadly threat,” said BIO’s President and CEO, Jim Greenwood. “I am pleased to see the Administration take action on this vitally important issue. BIO shares the Administration’s strong commitment to investing in and promoting novel technologies that will help address these challenges in way that protects both the public’s health and our nation’s security.”

Read the full executive order here.

Read the Council of Economic Advisers report here.